

13.10.2017 r.**MODULE 1 - Regulatory Update: Falsified Medicines, Medical Devices – New Legislation, Update of Clinical Trials****Moderators: prof. Tatyana Benisheva, prof. Dobriana Sidjimova**

Time	Theme
09:00 - 11:15	Falsified Medicines - Regulatory Update
	Medical Devices Regulation from 25.05.2017 Update
	Analysis Methods - biochemical and genetics
	Holistic marketing
11:15 - 11:30	Coffee break
11:30 - 14:00	Update of Clinical Trials legislation
	Drug development success rates. Medical statistics made easy
	Reference pricing in EU
	Biosimilarals, exchangeability, HTA
	Brexit and consequences for CAs and MAHs

03.11.2017 r.**MODULE 2 - Pharmacovigilance - Part I****Moderator - Prof. Dr. Barbara Sickmuller**

Time	Theme
09:00 - 09:45	Regulatory authorities and requirements
	Pharmacovigilance system
	Pharmacovigilance master file system
	QPPV
	Role of the Regulatory authorities.
09:45 - 10:15	PRAC - role and functions - update
10:15 - 10:45	Collection and management of pharmacovigilance data after receipt of a marketing authorisation
	EMA Guidance on Medication errors
	Off label Use - EMA Guideline - Module VI
10:45 - 11:00	Coffee break
11:00 - 13:00	Assessment of pharmacovigilance information
	Ongoing safety evaluation
	Regulatory requirements relating to signal detection
	Assessment of signals and benefit/risk ratio
	Risk management systems and risk management plans
	Intensified monitoring
	Referral procedures
13:00 - 14:00	Lunch break
14:00 - 15:00	New Pharmacovigilance requirements for marketed products in the EU
	PASS/PAES
	PSUR/PBRER
	Educational material
15:00 - 15:30	Procedural documentation, quality system and pharmacovigilance
	Pharmacovigilance System Master File – update
	Signal Detection
	Updated pharmacovigilance topics for discussion
15:30 - 16:00	Coffee break
Moderator - Prof. Dr. Barbara Sickmuller	
16:00 - 17:00	Pharmacovigilance inspections
	Purpose and scope of inspections in the EU
	Preparation for a pharmacovigilance inspection (Inspection readiness)
	Conducting a pharmacovigilance inspection
	When things are not going well
	Corrective actions after a regulatory pharmacovigilance inspection, CAPA handling

24.11.2017

MODULE 3 - Pharmacovigilance - Part II

Time	Theme
09:00 - 10:30	Collection and management of pharmacovigilance data after receipt of a marketing authorisation
	Literature monitoring - MLM Service (0.5 h)
	PSURs (0.5 h)
	PV in pre – approval - DSUR
	Regulatory reporting requirements
	PV agreements. Safety management plan and responsibilities
	PV in Clinical Trials , Medication Errors & Off Label Use - pre clinical examples
10:30 - 11:00	Coffee break
11:00 - 13:00	Pharmacovigilance and contractual interrelations with third parties
	Scope of contractual agreements as regards pharmacovigilance
	Regulatory requirements relating to contractual agreements
	Contractual agreements between pharmaceutical companies
	Contractual agreements with service suppliers regarding to pharmacovigilance
	Drawing up and maintenance of pharmacovigilance agreements
	Collection and management of pharmacovigilance data after receipt of a marketing authorisation
	MedDRA Dictionary (0.5)
	EV and signal detection by MAHs (0.5h)
	GVP Updates (45 min.)
13:00 - 14:00	Lunch break
14:00 - 15:30	The Role of Pharmacovigilance Department within the Company
	Interactive sessions - Simulation of crisis (case in situ) and selfinspections (0.5 h)